Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 32
Filter
1.
Cancer Res ; 50(1): 185-92, 1990 Jan 01.
Article in English | MEDLINE | ID: mdl-2293554

ABSTRACT

We performed a phase Ia/Ib study of interleukin 2 (IL2) in patients with cancer. Single doses of IL2 from 10(3) units/m2 to 10(7) units/m2 were well tolerated but failed to induce significant immunological changes. Chronic IL2 treatment for 5 days out of 7 for 3 weeks was well tolerated at doses below 10(7) units/m2 and was accompanied by significant immunological changes. Following chronic treatment with intramuscular injections of IL2 at 1 x 10(6) units/m2, we observed augmentation of peripheral blood natural killer activity and induction of peripheral blood LAK activity. Induction of LAK activity was most evident when IL2 was included in the cytotoxicity assay. There was a marked increase in the number of peripheral blood mononuclear cells bearing the Leu-19 marker in association with the observed increases in natural killer and LAK activity. A small percentage of Leu-19+ cells coexpressed CD3. There was heterogeneous expression of the low affinity Fc receptor (CD16). In vivo induced Leu-19+ cells could be divided into two populations, dim and bright, based on the intensity of fluorescent staining with antibodies to Leu-19. The majority of Leu-19 bright cells were CD16- while the majority of Leu-19 dim cells were CD16+. In addition, the intensity of CD16 staining was higher for Leu-19 dim cells than for Leu-19 bright cells. Increases in the amounts of CD38 and CD8 antigens were also observed. Significant increases in serum levels of the soluble IL2 receptor were observed during treatment. One partial remission was noted in a woman with non-Hodgkin's lymphoma.


Subject(s)
Interleukin-2/therapeutic use , Lymphocytes/immunology , Neoplasms/drug therapy , Cell Line , Cytotoxicity, Immunologic , Drug Evaluation , Female , Flow Cytometry , Humans , Injections, Intramuscular , Injections, Intravenous , Injections, Subcutaneous , Interleukin-2/administration & dosage , Interleukin-2/adverse effects , Killer Cells, Lymphokine-Activated/immunology , Killer Cells, Natural/immunology , Lymphocyte Activation/drug effects , Lymphocytes/drug effects , Male , Middle Aged , Monocytes/pathology , Neoplasms/immunology , Recombinant Proteins/administration & dosage , Recombinant Proteins/adverse effects , Recombinant Proteins/therapeutic use
2.
J Natl Cancer Inst ; 81(8): 602-11, 1989 Apr 19.
Article in English | MEDLINE | ID: mdl-2495368

ABSTRACT

Lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2) were administered by the ip route to patients with intra-abdominal malignancies. Pharmacokinetic studies of IL-2 revealed 10- to 100-fold higher concentrations of IL-2 in peritoneal fluid versus serum. Ip levels of IL-2 were maintained well above those required to generate and maintain LAK cells in vitro. LAK cell activity was detectable in the peritoneal fluid for the duration of each treatment cycle and did not disappear until IL-2 was discontinued. Detection of interferon-gamma (IFN-gamma) in the peritoneal fluid of all patients was consistent with production in situ by activated lymphocytes. In some patients, low but detectable levels of IFN-gamma were also found in the serum. In vivo activation of monocytes in the peritoneal fluid as measured by in vitro production of hydrogen peroxide was documented in the majority of patients. Neither interleukin-1 nor tumor necrosis factor-alpha was detected in the peritoneal fluid. We found no correlation between the presence or levels of IL-2, IFN-gamma, or LAK cell lytic activity in peritoneal fluid or serum and response or nonresponse to therapy.


Subject(s)
Abdominal Neoplasms/therapy , Interleukin-2/administration & dosage , Killer Cells, Natural/transplantation , Abdominal Neoplasms/immunology , Ascitic Fluid/immunology , Humans , Injections, Intraperitoneal , Interferon-gamma/metabolism , Interleukin-2/pharmacokinetics , Killer Cells, Natural/immunology , Lymphocyte Activation , Monocytes/metabolism , Predictive Value of Tests , Tumor Necrosis Factor-alpha/metabolism
3.
Blood ; 71(5): 1304-9, 1988 May.
Article in English | MEDLINE | ID: mdl-3129046

ABSTRACT

Activated T cells synthesize and express a cell membrane-bound receptor for interleukin-2 (IL-2) and have recently been shown to secrete a soluble form of the same receptor. Hairy cell leukemia is a chronic disorder caused by expansion of a clonal population of an unusual mononuclear cell of B cell origin. These cells have previously been shown to express an IL-2 receptor on the cell membrane. The sera of 26 patients with hairy cell leukemia were examined for the presence of a soluble IL-2 receptor before and during therapy with either recombinant interferon alpha-2a or 2'-deoxycoformycin. Before therapy, all patients had markedly elevated levels of this soluble IL-2 receptor ranging from five to 60 times the highest level observed in normal control sera. In individual patients changes in the level during therapy correlated well with clinical assessments of tumor response; levels fell to near the normal range in patients responding to therapy. Patients not responding to interferon alpha had no significant change in the soluble IL-2 receptor level. These results suggest that hairy cells secrete a soluble IL-2 receptor and that serial measurements of the level of this receptor in the serum can be used as a noninvasive means to assess disease response to therapy.


Subject(s)
Biomarkers, Tumor/analysis , Leukemia, Hairy Cell/blood , Receptors, Immunologic/analysis , Coformycin/analogs & derivatives , Coformycin/therapeutic use , Humans , Interferon Type I/therapeutic use , Leukemia, Hairy Cell/therapy , Pentostatin , Receptors, Interleukin-2 , Recombinant Proteins/therapeutic use
4.
J Clin Oncol ; 6(3): 434-45, 1988 Mar.
Article in English | MEDLINE | ID: mdl-3127550

ABSTRACT

This study was undertaken to determine an immunologically active regimen for the administration of recombinant gamma-interferon (rIFN-gamma). The patient population included patients with completely resected melanoma, stage I (Clark's level IV or V) or stage II. All patients exhibited no evidence of disease (NED) at the time of the study. Patients received rIFN-gamma by intramuscular (IM) injection daily for 15 days at 0.0001 mg/m2, 0.001 mg/m2, 0.01 mg/m2, 0.1 mg/m2 (ten patients/group), or 0.25 mg/m2 (five patients). Interferon (IFN) was well tolerated, with non-dose-limiting constitutional symptoms occurring in the majority of patients at 0.1 mg/m2 and 0.25 mg/m2. All five patients receiving 0.25 mg/m2 developed elevated transaminase levels, which led to a discontinuation of therapy in one patient. Immunological activity was assessed by serial measurements of natural killer (NK) cell activity, hydrogen peroxide production by monocytes, and changes in expression of Fc receptors and human leukocyte class II antigen (HLA-DR) on monocytes. These changes were determined at baseline (X2), six to seven time points during rIFN-gamma therapy, and two times after the last dose of rIFN-gamma. No changes were observed at the two lowest doses. At the 0.01 mg/m2 dose, all parameters were elevated but not as consistently nor to the same levels as seen following administration of 0.1 mg/m2. At 0.25 mg/m2, H2O2 production was enhanced, but unlike at 0.1 mg/m2, it declined during the last few days of IFN therapy. Subcutaneous (SC) administration was compared with IM administration using the 0.1 mg/m2 dose. SC administration resulted in enhanced H2O2 production and Fc receptor expression by monocytes. More consistent elevations in peroxide generation and higher levels of Fc receptor expression were seen following SC administration. No significant difference was found between the two routes of administration. A comparison of two schedules, daily and three times weekly, suggested that monocyte activation may return to normal 72 hours after IFN administration. Of the doses tested, 0.1 mg/m2 administered daily appeared to be the most effective biological response modifier (BRM) regimen, and because of ease of administration, we favor the SC route.


Subject(s)
Interferon-gamma/administration & dosage , Melanoma/therapy , Dose-Response Relationship, Drug , Drug Administration Schedule , HLA-DR Antigens/analysis , Humans , Hydrogen Peroxide/metabolism , Injections, Intramuscular , Injections, Subcutaneous , Interferon-gamma/adverse effects , Killer Cells, Natural/immunology , Melanoma/immunology , Monocytes/drug effects , Monocytes/immunology , Monocytes/metabolism , Receptors, Fc/analysis
5.
Cancer Res ; 47(20): 5504-8, 1987 Oct 15.
Article in English | MEDLINE | ID: mdl-3498534

ABSTRACT

The current method for generating lymphokine-activated killer (LAK) cells for use in human clinical trials is both labor intensive and expensive. Therefore, we altered cell culture conditions to determine whether LAK cells with enhanced lytic activity could be generated. Culture of normal human peripheral blood leukocytes for 7 days generated LAK cells with 4-fold more lytic activity than culture for 3 days. Although cell viability over this 7-day period dropped from 94% on Day 3 to 73% by Day 7, the recovery of cells from culture increased from 61 to 106%. If cells were exposed to CO2, lytic activity was further enhanced by up to 30-fold. Culture at a density of 1 or 2.5 X 10(6) cells/ml caused no difference in cell viability, recovery, or LAK activity when cells were cultured for up to 4 days; however, when cells were cultured for longer times, an initial density of 1 X 10(6) cells/ml yielded maximal LAK activity. Several commercially available serum-free defined media as well as human serum albumin supported LAK cell activation comparable to serum-containing media over a 4-day culture period. One defined medium, AIM V, supported LAK cell activation over a 7-day period even when cells were cultured at a density twice as high (2 X 10(6) cells/ml) as cells cultured in serum-containing medium. The results demonstrate that simple manipulation of human LAK cell culture conditions generates cells with greatly enhanced lytic activity and that serum-containing medium may not be necessary for generating LAK cells under the current clinical protocols.


Subject(s)
Interleukin-2/pharmacology , Killer Cells, Natural/immunology , Cells, Cultured , Culture Techniques/methods , Cytotoxicity, Immunologic , Humans , Killer Cells, Natural/drug effects , Recombinant Proteins/pharmacology
7.
Am J Hematol ; 22(2): 123-32, 1986 Jun.
Article in English | MEDLINE | ID: mdl-3706290

ABSTRACT

Twenty-two normal volunteers had approximately eight, 2-hr-long leukapheresis procedures over a 2-year period and their natural killer (NK) cell function was prospectively measured. The NK activity of the preprocedure peripheral blood (pre-PB) was found to correlate well with the NK activity of the inital leukocytes removed by leukapheresis (I-Leuk). When the I-Leuk specimens were compared with the leukapheresis specimens removed at the termination of leukapheresis (T-Leuk), T-Leuk showed a consistent 10% increase in NK activity. When the pre-PB and the I-Leuk values were analyzed for each donor over the 2 years of the study, 18 donors revealed no significant change from their baseline NK activity, two donors showed a minimal increase in NK cell activity, and two donors displayed a minimal decrease in NK cell activity. We conclude that although leukapheresis appears acutely to boost NK cell activity, this increase is transient and small in magnitude. Most importantly, repeated leukapheresis does not appear adversely to effect this important effector function in normal donors.


Subject(s)
Killer Cells, Natural/immunology , Leukapheresis/adverse effects , Adolescent , Adult , Humans , Middle Aged
8.
Blood ; 67(4): 1077-82, 1986 Apr.
Article in English | MEDLINE | ID: mdl-2937469

ABSTRACT

Patients with hairy cell leukemia (HCL) and chronic lymphocytic leukemia (CLL) were treated with recombinant interferon alpha A (rIFN-alpha A). The binding of iodinated recombinant interferon-alpha to baseline samples of peripheral blood mononuclear cells (PBMCs) from the leukemia patients was compared with clinical responsiveness to rIFN-alpha A. HCL patients (8/10) responded to rIFN-alpha A therapy, whereas none (0/10) of the CLL patients studied responded. The PBMCs from the eight responsive HCL patients bound approximately twice as much iodinated interferon as the PBMCs from nonresponsive CLL patients. This difference was due to more high-affinity receptors per cell with no difference in the affinity of the interferon-receptor interaction. However, because PBMCs from HCL patients were larger than PBMCs from CLL patients, the cell surface receptor density was similar. The leukemic cells from one of the two nonresponsive HCL patients bound iodinated interferon similarly to the cells from the responsive HCL patients, whereas the leukemic cells from the other nonresponsive HCL patient bound considerably less. The rapidity of response of the HCL patients did not correlate with the level of binding of iodinated interferon. Our results suggest that the absolute number of interferon receptors per cell may be only one of several important parameters in the response to rIFN-alpha A therapy, and that the responsiveness of a particular lymphoproliferative disease or a particular patient to rIFN-alpha A therapy cannot be predicted or explained solely by the degree of interaction between IFN and its cell surface receptor.


Subject(s)
Interferon Type I/blood , Leukemia, Hairy Cell/blood , Leukemia, Lymphoid/blood , Receptors, Immunologic/analysis , Recombinant Proteins/blood , Cell Separation/methods , Humans , Interferon Type I/therapeutic use , Leukemia, Hairy Cell/therapy , Leukemia, Lymphoid/therapy , Leukocyte Count , Receptors, Interferon , Recombinant Proteins/therapeutic use
9.
Am J Med ; 80(3): 351-6, 1986 Mar.
Article in English | MEDLINE | ID: mdl-3953613

ABSTRACT

Hairy cell leukemia is a lymphoproliferative disorder characterized clinically by cytopenias. Standard therapy following variable periods of disease stability consists of splenectomy that often restores normal hematologic parameters for periods ranging from weeks to years. Fifteen patients (five without prior splenectomy or chemotherapy) were treated with 3 X 10(6) units per day of recombinant leukocyte A interferon and 14 of 15 patients completed eight weeks of therapy and were evaluated for response. There was one complete and 12 partial responses for an overall response rate of 93 percent. All of these patients' conditions have remained in complete or partial remissions and they continue to receive interferon with a median follow-up of six months. Coincident with the normalization of peripheral blood counts was a return of natural killer activity and normalization of immunologic surface markers as determined by monoclonal antibodies. This study confirms and extends earlier observations with natural alpha-interferon and indicates that recombinant leukocyte A interferon in low daily doses is also very effective treatment for hairy cell leukemia. In fact, it may be the best single modality of therapy for inducing both hematologic and immunologic recovery of these patients and deserves consideration as initial therapy.


Subject(s)
Interferon Type I/therapeutic use , Leukemia, Hairy Cell/drug therapy , Adult , Aged , Antibodies, Monoclonal/immunology , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Flow Cytometry , Humans , Interferon Type I/administration & dosage , Killer Cells, Natural/immunology , Leukemia, Hairy Cell/immunology , Leukocyte Count , Male , Middle Aged
10.
J Biol Response Mod ; 5(1): 85-107, 1986 Feb.
Article in English | MEDLINE | ID: mdl-3514800

ABSTRACT

Six lymphoid human interleukin-2s (nIL-2s) [four from peripheral blood mononuclear cells (PBMC) and two from JURKAT cells] and six recombinant IL-2s (rIL-2s) were obtained for comparative evaluation. The main issues addressed were possible differences among the preparations in potency in T cell growth assays and other functional assays, and the possible presence of other cytokine activities or contaminants. Each preparation was assigned a standardized IL-2 activity in reference units (RU) by comparing its T cell growth promoting activity against the Biological Response Modifiers Program IL-2 (JURKAT) reference reagent. Relative to the IL-2 unitage indicated by the suppliers, the RU varied from 110-fold less to 38.5-fold more for the various preparations. Two nIL-2s and two rIL-2s contained significant levels of endotoxin. One nIL-2 contained low levels of both alpha and gamma interferon (IFN), and one nIL-2 had a high level of gamma IFN. All other IL-2s were negative for IFN activity. All IL-2 preparations significantly augmented human natural killer (NK) activity, although the amount of RU required varied from 0.1 to 50 RU. Four nIL-2s and three rIL-2s induced human PBMC to produce gamma IFN, whereas two nIL-2s and one rIL2 did not. All nIL-2s had substantial amounts of B cell growth factor activity, whereas none of the rIL-2s consistently displayed this activity. All IL-2s stimulated the tritiated thymidine [3H]TdR incorporation of human PBMC in the absence of other stimuli, in addition to augmenting the response to mitogen or alloantigens. Some nILs and IL-2s had effects on human monocytes such as inhibiting migration, inducing cytotoxic or growth inhibitory activity against tumor cells, and causing changes in cell surface markers. The IL-2s were also tested for activity in vitro and in vivo in mice. Although there was a 12-fold variation in activity among the preparations, all but one of the IL-2s showed augmentation of the mixed lymphocyte reaction activity and all IL-2s tested stimulated macrophage cytotoxicity in vitro. All IL-2s tested enhanced the mixed lymphocyte-allogeneic tumor cell reaction resulting in greater production of cytotoxic T cells. However, significant quantitative differences in potency were evident among the various IL-2 preparations, especially the nIL-2s. Only very high doses of IL-2 (intraperitoneal injection of 100,000 RU/animal) induced in vivo augmentation of splenic or peritoneal NK cells, although all IL-2s tested increased NK activity against tumor target cells in vitro with substantially lower doses (10-100 RU/ml).(ABSTRACT TRUNCATED AT 400 WORDS)


Subject(s)
Interleukin-2/isolation & purification , Animals , Biological Assay , Drug Evaluation, Preclinical , Humans , In Vitro Techniques , Interleukin-2/physiology , Lymphocyte Activation , Lymphocytes/immunology , Mice , Reference Standards , T-Lymphocytes/immunology
11.
Lymphokine Res ; 5 Suppl 1: S183-7, 1986.
Article in English | MEDLINE | ID: mdl-3784612

ABSTRACT

Phase I clinical trials of Biological Response Modifiers must be designed to provide information not only regarding toxicities, pharmacokinetics and anti-tumor response, but also on their many immunomodulatory properties. If BRMs are to be used rationally, then detailed standardized data must be obtained in such a way as to enable meaningful conclusions to be drawn from the monitoring assays. Assay selection, timing for monitoring and methods for data interpretation are important considerations in the design of such trials.


Subject(s)
Clinical Trials as Topic/methods , Immunotherapy , Lymphokines/therapeutic use , Monitoring, Physiologic/methods , Neoplasms/therapy , Drug Evaluation , Humans , Neoplasms/immunology
12.
J Biol Response Mod ; 4(6): 656-63, 1985 Dec.
Article in English | MEDLINE | ID: mdl-4087034

ABSTRACT

Poly(I,C)-LC was administered in low (1 mg/m2) and intermediate (4 mg/m2) doses to cancer patients by intramuscular injection or intravenous infusion to evaluate the immunomodulatory effects. Natural killer cell (NK) activity was elevated slightly at the low dose and remained unchanged overall, but some depression was observed at the 4 mg/m2 intravenous dose. Monocyte function was elevated in all groups of patients, as was the interferon-induced enzyme 2'5'-oligo-A synthetase. These increases were observed at the 1 mg/m2 intramuscular dose, despite a lack of detectable circulating serum interferon (IFN). In regard to cell surface markers, poly(I,C)-LC induced an increase in OKT10-positive cells and a small but consistent trend toward increases in the ratio of Leu-3/Leu-2-positive cells. Lymphocyte proliferation in response to concanavalin A was depressed by poly(I,C)-LC administration. Although an optimum immunomodulatory dose and schedule was not determined, the data indicate that low doses produce significant changes in immune function and that induction of detectable levels of circulating interferon is not required for poly(I,C)-LC to have biological effects.


Subject(s)
Adjuvants, Immunologic , Carboxymethylcellulose Sodium/therapeutic use , Methylcellulose/analogs & derivatives , Neoplasms/drug therapy , Poly I-C/therapeutic use , Polylysine/therapeutic use , 2',5'-Oligoadenylate Synthetase/blood , Carboxymethylcellulose Sodium/administration & dosage , Drug Evaluation , Humans , In Vitro Techniques , Killer Cells, Natural/drug effects , Killer Cells, Natural/immunology , Leukocytes/classification , Leukocytes/drug effects , Lymphocyte Activation/drug effects , Monocytes/drug effects , Monocytes/immunology , Neoplasms/blood , Neoplasms/immunology , Poly I-C/administration & dosage , Polylysine/administration & dosage
13.
J Immunol ; 135(4): 2483-91, 1985 Oct.
Article in English | MEDLINE | ID: mdl-2411797

ABSTRACT

Augmentation of natural killer (NK) cell activity has been observed after the single administration of a wide variety of biological response modifiers (BRM); however, multiple injections of BRM have resulted in hyporesponsiveness to NK augmentation in both preclinical and clinical studies. In these studies, hyporesponsiveness to augmentation of NK cell activity occurred after multiple injections of interferon (IFN recombinant human IFN-alpha A/D and recombinant IFN-gamma) and interleukin 2 and was found to be systemic (lungs, liver, blood, and spleen). In contrast, hyporesponsiveness to augmentation by multiple injections of maleicanhydride divinyl ether (MVE-2) or Propionibacterium acnes was limited to the spleen and peripheral blood lymphocytes, with continued augmentation of NK cell activity in the peritoneum, lungs, and liver. Despite the hyporesponsiveness to augmentation of NK activity by multiple IFN injections, NK activity could still be augmented by a single injection of another BRM. The NK cell hyporesponsiveness induced in the spleen by MVE-2 was also reversed by a single administration of IFN or polyinosinic-polycytidylic and poly-L-lysine solubilized by carboxymethyl cellulose but not by OK-432 or P. acnes. These results demonstrate that the nature of the hyporesponsiveness to NK augmentation, which is induced by multiple treatments with BRM, varies with the type of agent. The noncytokine BRM that were studied induced hyporesponsiveness only in specific lymphoid compartments but not in major nonlymphoid organs, whereas cytokine BRM induced a systemic hyporesponsiveness. The hyporesponsive state induced by the different types of BRM, also varied in regard to the pattern of susceptibility to augmentation of NK activity by unrelated BRM.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Cytotoxicity, Immunologic , Immune Tolerance , Interferons/administration & dosage , Interleukin-2/administration & dosage , Killer Cells, Natural/immunology , Animals , Biological Products/pharmacology , Carboxymethylcellulose Sodium/administration & dosage , Cytokines , Cytotoxicity, Immunologic/drug effects , Humans , Immune Tolerance/drug effects , Liver/immunology , Lung/immunology , Male , Mice , Mice, Inbred C3H , Mice, Inbred C57BL , Organ Specificity , Poly I-C/administration & dosage , Polylysine/administration & dosage , Pyran Copolymer/administration & dosage , Spleen/immunology
14.
Cancer Treat Rep ; 69(10): 1165-9, 1985 Oct.
Article in English | MEDLINE | ID: mdl-3899356

ABSTRACT

During the past several years, increasing attention has been devoted to the use of biological response modifiers (BRMs) for the treatment of cancer. Phase I trials of BRMs must be designed to provide information not only regarding toxic effects, pharmacokinetics, and antitumor activities, but also on the many immunomodulatory effects. Biological monitoring must be carefully planned to enable meaningful conclusions to be drawn as to the optimal dose, schedule, and route of administration. Important considerations include selection of assays for the various biological effects, timing of testing following BRM administration, and methods for data interpretations.


Subject(s)
Biological Products/therapeutic use , Clinical Trials as Topic/standards , Neoplasms/therapy , Animals , Colony-Stimulating Factors/immunology , Dose-Response Relationship, Immunologic , Humans , Immunocompetence/drug effects , Immunologic Techniques , Immunotherapy , Mice , Neoplasms/immunology , Research Design/standards
15.
Cancer Immunol Immunother ; 20(3): 193-7, 1985.
Article in English | MEDLINE | ID: mdl-3933818

ABSTRACT

A total of 11 patients were treated on an escalating, single dose trial of recombinant gamma interferon (rIFN-gamma), 6 patients by the i.m. and 5 patients by the i.v. route of administration. Dose ranges within each individual were from 0.05 mg/m2 of IFN (1 mg greater than or equal to 10 X 10(6) units of IFN) escalating to 10 mg/m2. All dosages were delivered twice weekly and the i.v. dose was infused over 5 min. The most common toxicities encountered included fever, chills, fatigue, anorexia, and granulocytopenia. The influenza-like symptoms were very similar to those encountered with IFN-alpha but were generally less severe. The granulocytopenia was dose-related and transient with recovery generally seen within 48-72 h following administration of rIFN-gamma. Absolute granulocyte counts only rarely dropped below 1000 mm3. Hepatotoxicity was not observed. IFN levels were determined by both a bioassay and an enzyme-linked immunosorbent assay. By the i.v. route, the peak level of IFN activity could usually be seen at completion of the infusion with a serum half-life of 30 min. By the i.m. route, the peak level of serum activity was generally detected between 4-8 h with a serum half-life of 4.5 h after the initial elimination phase. Peak IFN levels appeared to correlate with maximum toxicity. One patient with melanoma had a 25% reduction in a cutaneous lesion, but there were no other minimal, partial, or complete responses.


Subject(s)
Interferon-gamma/therapeutic use , Neoplasms/therapy , Recombinant Proteins/therapeutic use , Drug Evaluation , Humans , Immunotherapy , Interferon-gamma/blood , Interferon-gamma/toxicity
16.
J Biol Response Mod ; 3(6): 634-52, 1984 Dec.
Article in English | MEDLINE | ID: mdl-6334720

ABSTRACT

The biological response modifier maleic anhydride-divinyl ether (MVE-2) can activate natural killer (NK) cells and macrophages and can act as an immunoadjuvant for T and B cells. MVE-2 activates macrophages following intravenous or intraperitoneal injection in a compartmentalized manner, i.e., peritoneal macrophages (i.p. injection) or alveolar macrophages (i.v. injection). It activates NK cells in vivo but not in vitro, a dichotomy that may be secondary to interferon production. Splenic NK cell activity is not prolonged by the multiple injection of MVE-2; instead, it induces a state of NK cell hyporesponsiveness, which may limit its therapeutic efficiency. Therapeutic properties of MVE-2 are largely limited to nonspecific immunoprophylaxis, which may be associated with NK cell activation but which does not necessarily correlate with the level of splenic NK cell activation. Minimal therapeutic efficiency consisting of a slight prolongation in survival is observed in mice with preexistent disease treated with MVE-2. Prolonged survival is observed only in those animals placed on therapy soon after tumor cell challenge (experimental metastasis) and not in mice with established spontaneous metastasis. The need to manipulate the animal model (MVE-2 injection prior to or rapidly following tumor challenge) seems to predict that this agent is unlikely to be clinically useful against preexistent metastatic tumor burden, although some efficiency may be associated with local treatment into the pleural or peritoneal cavity.


Subject(s)
Neoplasms, Experimental/therapy , Polymers/immunology , Pyran Copolymer/immunology , Adjuvants, Immunologic , Animals , Antibody Formation , Cell Line , Cytotoxicity, Immunologic , Immunity, Cellular , Immunotherapy , Killer Cells, Natural/immunology , Lymphocyte Activation , Macrophage Activation , Macrophages/immunology , Male , Mice , Mice, Inbred Strains , Neoplasm Metastasis , Pyran Copolymer/therapeutic use , T-Lymphocytes, Cytotoxic/immunology
17.
J Am Acad Dermatol ; 11(2 Pt 1): 197-202, 1984 Aug.
Article in English | MEDLINE | ID: mdl-6384282

ABSTRACT

The susceptibility of human papillomavirus infection to polyclonal human leukocyte interferon (IFN-alpha) has been evaluated in patients with epidermodysplasia verruciformis (EV), a disease with extensive chronic papillomavirus-induced warts. In a double-blind, placebo-controlled study with intralesional IFN-alpha, four of five IFN-alpha-treated warts regressed; none of the placebo-treated warts responded (p = 0.024). Three patients with EV were treated with systemic IFN-alpha for 4 weeks in an open study, achieving partial regression of warts in all three. In a double-blind, placebo-controlled study, warts in two children with EV regressed with systemic IFN-alpha while two who received placebo showed no improvement. The lesions recurred following cessation of therapy. At the completion of therapy with IFN-alpha, histologic normalization was accompanied by a 95% decrease in the number of viral antigen-containing cells in the warts (p less than 0.001). We conclude that warts in EV respond to systemic and intralesional IFN-alpha.


Subject(s)
Interferon Type I/therapeutic use , Skin Diseases/therapy , Warts/therapy , Adult , Child , Child, Preschool , Clinical Trials as Topic , Female , Humans , Male , Middle Aged , Skin/pathology , Warts/immunology , Warts/pathology
18.
J Immunol ; 131(1): 503-7, 1983 Jul.
Article in English | MEDLINE | ID: mdl-6863923

ABSTRACT

One hundred thirty-four patients with a variety of malignancies were treated in two phase I clinical trials of recombinant leukocyte A interferon (IFL-rA) produced by recombinant DNA methodology. IFL-rA was given by intra-muscular injection either twice daily or three times weekly for 28 days. Extensive monitoring of natural killer (NK) cell cytotoxicity was done on these patients with rigorously standardized assays and determination of the inherent variability of NK function for each individual. Interferon, as used in these two treatment regimens, failed to produce an appreciable increase in NK activity; in the majority of patients, there was no significant change in NK activity from the pretreatment baseline levels. An unexpected finding was the depression of NK activity in 30% of the patients. The data have been analyzed in terms of their possible relationship to dose and schedules of IFL-rA administration and to antitumor response.


Subject(s)
Cytotoxicity, Immunologic , Immune Tolerance , Interferon Type I/administration & dosage , Killer Cells, Natural/immunology , Analysis of Variance , Dose-Response Relationship, Immunologic , Female , Humans , Male , Neoplasms/therapy
19.
J Biol Response Mod ; 2(5): 470-81, 1983.
Article in English | MEDLINE | ID: mdl-6358423

ABSTRACT

Patients with a variety of malignancies were treated in phase I clinical trials of recombinant leukocyte A interferon (IFL-rA) schedules consisting of either twice-daily doses for 28 days (48 patients) or three times weekly for 28 days (86 patients). Extensive monitoring of several immune functions was done on these patients, with rigorously standardized assays and determination of inherent variability of function for each individual. The assays performed were natural killer (NK) cell cytotoxicity, monocyte cytostatic activity, lymphoproliferative responses to concanavalin A (con A) and mixed leukocyte culture, and an analysis of changes in leukocyte populations as determined using a panel of monoclonal antibodies and flow cytometry. No appreciable increase in NK activity was observed on any of the treatment regimens, and an unexpected observation was the depression of activity in a substantial proportion (30%) of patients. In contrast, monocyte function, as measured in an assay of growth inhibition of tumor target cells, was found to be elevated in 70% of the patients. Lymphoproliferative responses were depressed in most patients in response to both con A and the mixed leukocyte culture. Cell surface marker studies revealed an increase in the percentage of OKT10 positive cells in the majority of patients studied and a transient increase in cells reacting with the antibody MO2. The data have been analyzed in terms of their relationship to dose and schedule of administration, and the depression of NK activity was shown to be greatest at the highest doses and more frequent schedule of administration.


Subject(s)
Interferon Type I/therapeutic use , Neoplasms/therapy , Clinical Trials as Topic , Dose-Response Relationship, Immunologic , Humans , Interferon Type I/immunology , Killer Cells, Natural/immunology , Monocytes/immunology , Neoplasms/immunology
20.
J Neural Transm ; 58(1-2): 99-106, 1983.
Article in English | MEDLINE | ID: mdl-6655470

ABSTRACT

The cytotoxic potential of mononuclear blood cells from 27 chronic schizophrenic patients was evaluated using quantitative measures of natural killer cell activity and macrophage inhibition of tumor cell growth. 44% of the patients had some evidence of deficient in vitro mononuclear cell function which was not correlated with a qualitative or quantitative alteration in the histologic appearance of these peripheral blood cells.


Subject(s)
Cytotoxicity, Immunologic , Killer Cells, Natural/immunology , Macrophages/immunology , Schizophrenia/immunology , Adult , Chronic Disease , Humans , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...